MorphoSys AG
16.7.2021 19:53:31 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to implement the purchase of 1,337,552 new ordinary shares by Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc (NASDAQ: RPRX) ("Royalty Pharma"). The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
"We're pleased that Royalty Pharma is taking an equity position in MorphoSys as part of the long-term strategic finance partnership the two companies entered into this year," said Sung Lee, Chief Financial Officer of MorphoSys.
Royalty Pharma's share purchase in the aggregate amount of US$ 100 million is part of the funding agreement with MorphoSys for the now completed acquisition of Constellation Pharmaceuticals; the agreement has become effective upon the completion of the merger on 15 July 2021. Royalty Pharma has purchased the 1,337,552 new ordinary shares at a price of € 63.35 per share, the volume-weighted average price of MorphoSys shares five trading days on the Frankfurt Stock Exchange (Xetra) prior to the merger, representing a premium of 12.1% to today's closing market price on the Frankfurt Stock Exchange (Xetra). The new MorphoSys shares will be listed on the Frankfurt Stock Exchange. Royalty Pharma has agreed, subject to limited exceptions, not to sell or otherwise transfer any of the new ordinary shares for a period of twelve months.
About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com.
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
MorphoSys Contacts:
Investor Contact
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@MorphoSys.com
Myles Clouston
Senior Director
Tel: +1 857-772-0240
myles.clouston@MorphoSys.com
Media Contact
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 89927 26079
thomas.biegi@MorphoSys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
jeanette.bressi@MorphoSys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/655879/MorphoSys-Concludes-a-US-100-Million-Capital-Increase-to-Implement-the-Purchase-of-1337552-shares-by-Royalty-Pharma
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development28.10.2026 16:50:00 CET | Press release
NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36 million of a contract valued up to US $99 million from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC). The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as
GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B28.10.2026 16:00:00 CET | Press release
SAN DIEGO, CA / ACCESS Newswire / October 28, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has partnered with Saab to perform advanced flight testing of an Airborne Early Warning (AEW) system on an Uncrewed Aircraft System (UAS). The flight testing was conducted over the past few months using a GA-ASI-produced MQ-9B carrying a Saab LoyalEye radar operating from GA-ASI's Desert Horizon flight operations facility in Southern California. The flight test demonstrated simultaneous tracking of several airborne and maritime targets at long ranges. The airborne targets tracked included multiple instrumented red fighter jets and several commercial aircraft. MQ-9B is GA-ASI's flagship UAS, offering unmatched endurance, type certification and all-weather performance. GA-ASI is discussing unmanned AEW capabilities on MQ-9B with several customers. "This has been one of the most highly anticipated flight tests we have performed," said GA-ASI President David R. Alexander. "The level of
Juno Corp. Closes $25 Million Non-Brokered Private Placement28.10.2026 12:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / October 28, 2026 / Juno Corp. ("Juno" or the "Company"), the largest mineral claim holder and most active explorer in Ontario's Ring of Fire, is pleased to announce that it has completed a non-brokered private placement (the "Offering") for aggregate gross proceeds of $25,290,609. Pursuant to the Offering, the Company issued an aggregate of (i) 165,750 common shares of Juno ("HD Juno Shares"), on a non-flow-through basis at a price of $4.00 per HD Juno Share, (ii) 404,890 common shares of Juno that qualify as "flow-through shares" as defined in subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act") (the "FT Juno Shares"), at a price of $4.50 per FT Juno Share, and (iii) 4,131,450 common shares of Juno, which qualify as "flow-through shares" as defined in subsection 66(15) of the Tax Act (the "Premium FT Juno Shares", and together with the HD Juno Shares and the FT Juno Shares, the "Juno Securities"), at a price of $5.52 per Premium FT Juno Shar
DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform27.10.2026 15:55:00 CET | Press release
OTTAWA, ON / ACCESS Newswire / October 27, 2026 / DistillerSR® Inc., the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Since September 2025, DistillerSR Agentic AI has eliminated evidence silos at customer organizations by connecting Large Language Models to a repository of expertly validated literature evidence. Smart Chat now makes that same capability available natively within DistillerSR's secure platform. "While researchers recognize the power of generative AI, many life sciences organizations cannot risk connecting external LLMs to their sensitive research data," said Peter O'Blenis, CEO of DistillerSR. "Smart Chat removes that barrier. It is built directly into the platform teams already use, works exclusively with their own DistillerSR projects, and is included with every version of DistillerSR." Smart Chat works only wit
PuK Gaming Launches First Officially Licensed Fortnite Mobile Accessories Range27.10.2026 14:15:00 CET | Press release
LONDON, UK / ACCESS Newswire / October 27, 2026 / PuK Gaming LTD, the UK-based designer of premium mobile gaming accessories, today launched Drop 1 of its officially licensed Fortnite range, in a deal facilitated by Epic Games' licensing agency IMG Licensing. The five-product range offers console-grade control to how millions play Fortnite: on a phone. The PuK Thumbstick, PuK Triggers, PuK Link Cable and PuK Thumb Sleeves attach in seconds, no battery charge or pairing required; the whole ecosystem fits in your pocket. The Hot Drop Bundle includes three of the four products, plus a collector tin and zip case. Every Drop 1 product includes a code for a bonus in-game item, with the Thumbstick granting the Stage Dive Glider and the Hot Drop Bundle granting the Battle Call Emote. "Fortnite defines competitive play for mobile gamers," said Scotty Tidwell, CEO of PuK Gaming. "Drop 1 gives Fortnite players more ways to play on mobile with console-grade low-latency control and precision." PuK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom